FLOLIPID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLOLIPID (FLOLIPID).
Flolipid (simvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.
| Metabolism | Simvastatin is a prodrug; the lactone ring is hydrolyzed in vivo to the active β-hydroxyacid form. It is extensively metabolized by CYP3A4 and also undergoes glucuronidation. Major metabolites include the active β-hydroxyacid and 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives. |
| Excretion | Primarily hepatic metabolism with biliary excretion; approximately 90% of the dose is recovered in feces, and less than 10% in urine, mainly as metabolites. |
| Half-life | Terminal elimination half-life is approximately 3 to 4 hours; however, due to extensive enterohepatic recirculation, the clinical duration of action is longer, allowing for once-daily dosing. |
| Protein binding | More than 99% bound, primarily to albumin. |
| Volume of Distribution | Approximately 0.4 L/kg, indicating distribution into extravascular tissues; not extensively bound to tissues. |
| Bioavailability | Oral bioavailability is not applicable as Flolipid is an intravenous lipid emulsion; bioavailability is 100% via intravenous route. |
| Onset of Action | Oral: Onset of lipid-lowering effect occurs within 2 to 4 weeks of starting therapy; maximum effect typically seen after 4 to 8 weeks. |
| Duration of Action | Duration of lipid-lowering effect persists for at least 24 hours with once-daily dosing; continued effect requires sustained treatment; discontinuation leads to return to baseline lipid levels within several weeks. |
Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.
| Dosage form | SUSPENSION |
| Renal impairment | For GFR 30 to <60 mL/min/1.73 m²: maximum dose 2 mg once daily. For GFR <30 mL/min/1.73 m²: not recommended. |
| Liver impairment | Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. No specific Child-Pugh-based dosing adjustments provided; use with caution in mild hepatic impairment. |
| Pediatric use | For patients 8 years and older with heterozygous familial hypercholesterolemia: 2 mg orally once daily; may increase to 4 mg once daily after 4 weeks. |
| Geriatric use | No dose adjustment required; monitor for increased risk of myopathy and renal function in patients over 65 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLOLIPID (FLOLIPID).
| Breastfeeding | Breastfeeding is contraindicated during rosuvastatin therapy. M/P ratio: unknown. Rosuvastatin is excreted in rat milk; human data absent. Potential for serious adverse reactions in nursing infants. |
| Teratogenic Risk | FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotoxicity. Second and third trimesters: Statins may reduce fetal cholesterol synthesis; risk of fetal harm cannot be excluded. Use only if pregnancy risk accepted. |
■ FDA Black Box Warning
Simvastatin is contraindicated for use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone) and with gemfibrozil, cyclosporine, or danazol. Do not exceed 20 mg simvastatin daily with amiodarone, amlodipine, or ranolazine. Do not exceed 40 mg simvastatin daily with lomitapide or diltiazem. Avoid grapefruit juice. Increased risk of myopathy/rhabdomyolysis with these drugs.
| Serious Effects |
["Hypersensitivity to any component of Flolipid","Active liver disease or unexplained persistent elevations of serum transaminases","Concomitant use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone)","Concomitant use of gemfibrozil, cyclosporine, or danazol","Pregnancy and breastfeeding","Women of childbearing potential unless using effective contraception"]
| Precautions | ["Myopathy/Rhabdomyolysis: Risk factors include age >65 years, female, renal impairment, uncontrolled hypothyroidism, and concomitant use of certain drugs (see Black Box Warning).","Hepatic effects: Persistent elevations in serum transaminases; recommend liver enzyme monitoring before and during treatment.","Increased risk of diabetes mellitus: Small increase in fasting glucose and HbA1c.","Interstitial lung disease: Rare cases reported.","Use with caution in patients with predisposing factors for renal impairment."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal hepatic function (ALT, AST) and creatine kinase (CK) at baseline and periodically. Assess for muscle symptoms. In pregnancy, monitor fetal growth via ultrasound if inadvertent exposure. |
| Fertility Effects | No known significant effects on human fertility. Animal studies show no impairment of fertility at clinically relevant doses. |